Latest news with #Biotricity
Yahoo
a day ago
- Business
- Yahoo
Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a significant milestone by reporting positive EBITDA for the first time in its history, indicating a path towards profitability. The company reported a 21% increase in revenue for the first quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of its technology. Biotricity Inc (BTCY) has expanded its cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's Tensorflow, enhancing diagnostic accuracy and patient outcomes. The company has secured regulatory approvals in multiple international markets, including Canada, Saudi Arabia, and Argentina, aligning with its strategy for global expansion. Gross profit for the quarter increased by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%, reflecting operational efficiencies and a strong recurring revenue base. Negative Points Despite improvements, Biotricity Inc (BTCY) reported a net loss of $754,000 for the first quarter, although this was a significant improvement from the prior year's loss. The company faces challenges with rising variable interest rates, which could impact future financial performance. Biotricity Inc (BTCY) is still in the process of pursuing FDA clearance for its AI clinical model, which could delay the full commercialization of its new technologies. Operating expenses, although reduced, remain a concern as the company continues to invest in R&D and sales force transformation. The company's expansion into new verticals and international markets may require significant resources and could face regulatory and competitive challenges. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with BTCY. Q: Can you provide more details on the strategic partnerships mentioned in the call? A: Dr. Walkus Al Sadiq, CEO, highlighted that Biotricity has formed strategic partnerships with industry giants like Amazon AWS and Google's Tensorflow to expand their cardiac AI cloud platform. These partnerships are crucial for enhancing diagnostic accuracy and improving patient outcomes. Additionally, alliances with three major group purchasing organizations (GPOs) in the US provide access to approximately 90% of hospitals, significantly expanding market access. Q: What are the financial highlights for the first quarter of fiscal 2026? A: Johnny Abo, CFO, reported a 21% increase in revenue to $3.9 million compared to the previous year. Gross profit rose by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%. Operating expenses decreased by 18.5%, and the company achieved a positive EBITDA of $333,000, marking the first quarter of positive EBITDA in Biotricity's history. Q: How is Biotricity addressing the market for atrial fibrillation monitoring? A: The CFO emphasized that atrial fibrillation, a major contributor to strokes, remains a significant focus. Biotricity's technology has monitored over 2 trillion heartbeats, providing early intervention opportunities and improving patient outcomes. This focus not only enhances patient care but also offers potential healthcare cost savings. Q: What are the future growth prospects for Biotricity? A: Dr. Walkus Al Sadiq, CEO, expressed optimism about future growth through the commercialization of products like Biocore Pro, Bioflux, and Biocare. The company is committed to advancing remote monitoring solutions and expanding its geographic footprint, with regulatory approvals in Canada, Saudi Arabia, Argentina, and other markets. Q: How has Biotricity managed to achieve cost efficiencies? A: The CFO explained that cost efficiencies were achieved through strategic transformation of the sales force, focusing on larger accounts and longer sales cycles. Additionally, the use of AI and automation, along with proactive cost management, contributed to positive free cash flows and a path towards profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
a day ago
- Business
- Yahoo
Biotricity Inc (BTCY) Q1 2026 Earnings Call Highlights: A Milestone Quarter with Positive ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a significant milestone by reporting positive EBITDA for the first time in its history, indicating a path towards profitability. The company reported a 21% increase in revenue for the first quarter of fiscal 2026, reaching $3.9 million, driven by strong market adoption of its technology. Biotricity Inc (BTCY) has expanded its cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's Tensorflow, enhancing diagnostic accuracy and patient outcomes. The company has secured regulatory approvals in multiple international markets, including Canada, Saudi Arabia, and Argentina, aligning with its strategy for global expansion. Gross profit for the quarter increased by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%, reflecting operational efficiencies and a strong recurring revenue base. Negative Points Despite improvements, Biotricity Inc (BTCY) reported a net loss of $754,000 for the first quarter, although this was a significant improvement from the prior year's loss. The company faces challenges with rising variable interest rates, which could impact future financial performance. Biotricity Inc (BTCY) is still in the process of pursuing FDA clearance for its AI clinical model, which could delay the full commercialization of its new technologies. Operating expenses, although reduced, remain a concern as the company continues to invest in R&D and sales force transformation. The company's expansion into new verticals and international markets may require significant resources and could face regulatory and competitive challenges. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with BTCY. Q: Can you provide more details on the strategic partnerships mentioned in the call? A: Dr. Walkus Al Sadiq, CEO, highlighted that Biotricity has formed strategic partnerships with industry giants like Amazon AWS and Google's Tensorflow to expand their cardiac AI cloud platform. These partnerships are crucial for enhancing diagnostic accuracy and improving patient outcomes. Additionally, alliances with three major group purchasing organizations (GPOs) in the US provide access to approximately 90% of hospitals, significantly expanding market access. Q: What are the financial highlights for the first quarter of fiscal 2026? A: Johnny Abo, CFO, reported a 21% increase in revenue to $3.9 million compared to the previous year. Gross profit rose by 31.9% to $3.1 million, with a gross profit margin improvement to 80.5%. Operating expenses decreased by 18.5%, and the company achieved a positive EBITDA of $333,000, marking the first quarter of positive EBITDA in Biotricity's history. Q: How is Biotricity addressing the market for atrial fibrillation monitoring? A: The CFO emphasized that atrial fibrillation, a major contributor to strokes, remains a significant focus. Biotricity's technology has monitored over 2 trillion heartbeats, providing early intervention opportunities and improving patient outcomes. This focus not only enhances patient care but also offers potential healthcare cost savings. Q: What are the future growth prospects for Biotricity? A: Dr. Walkus Al Sadiq, CEO, expressed optimism about future growth through the commercialization of products like Biocore Pro, Bioflux, and Biocare. The company is committed to advancing remote monitoring solutions and expanding its geographic footprint, with regulatory approvals in Canada, Saudi Arabia, Argentina, and other markets. Q: How has Biotricity managed to achieve cost efficiencies? A: The CFO explained that cost efficiencies were achieved through strategic transformation of the sales force, focusing on larger accounts and longer sales cycles. Additionally, the use of AI and automation, along with proactive cost management, contributed to positive free cash flows and a path towards profitability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company'), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America and opening the door to managed care programs, which is a new vertical strategy for Biotricity. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions." Q1-FY26 Financial Highlights Revenue increased 21% to $3.9 million, compared with $3.2 million in Q4 FY24 Gross margin was 80.5% for the three months ended June 30, 2025, as compared to 73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. Net loss decreased to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25; this was an 80.6% improvement even after removing the effects of a $3 million one-time deemed dividend in the corresponding prior year period. Positive EBITDA of $333,337, first time in the Company's history; EBITDA increased by 118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies. Operating Highlights for Q1-FY26 and the Future Q1-FY26 recurring (TaaS) Technology Fees rose a robust 11.8% from the corresponding period of the prior year, to $3.4 million, which is also 7.9% increase from the immediately preceding three-month period. Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution. Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of $35 billion. Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina. Expansion of geographic footprint across 70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US. Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update CallDate: Thursday, August 14, 2025Time: 4:30pm ET (1:30pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13755374Expiration: Thursday, August 28, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization ('EBITDA') is one such measure: 3 months endedJune 30,2025 3 months endedJune 30,2024 $ $ Net loss attributable to common stockholders (754,293 ) (6,948,292 ) Add: Provision for income taxes - - Interest expense 850,254 768,673 Accretion and amortization expenses 153,572 1,144,728 Depreciation 1,488 1,488 Preferred stock dividends 82,316 3,253,772 EBITDA 333,337 (1,779,631 ) Weighted average number of common shares outstanding 26,284,734 14,169,441 Profit (Loss) per Share, Basic and Diluted 0.013 (0.126 ) Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts Investor RelationsBiotricity Investor RelationsInvestors@ SOURCE: Biotricity Inc.
Yahoo
19-07-2025
- Business
- Yahoo
Biotricity Inc (BTCY) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Revenue (Q4 2025): $3.7 million, a 16.5% increase year-over-year. Revenue (Fiscal Year 2025): $13.8 million, up 14.3% from the prior year. Gross Profit (Q4 2025): $3 million, a 31% increase from the prior year period. Gross Margin (Q4 2025): 80.4%, an improvement of over 890 basis points from the prior year. Operating Expenses (Fiscal Year 2025): $13 million, a 24.5% decrease from the prior year. Net Loss (Fiscal Year 2025): $11.9 million, compared to $14.9 million in the prior year. Net Loss Per Share (Fiscal Year 2025): $0.555, compared to $1.66 in the prior year. Adjusted EBITDA (Q4 2025): Positive $438,000, corresponding to $0.017 per share. Adjusted EBITDA (Fiscal Year 2025): Loss of just under $1 million, improved from a loss of $7.8 million in fiscal '24. Warning! GuruFocus has detected 6 Warning Signs with BTCY. Release Date: July 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Biotricity Inc (BTCY) achieved a 16.5% year-over-year revenue increase in the fourth quarter, reaching $3.7 million. The company expanded its Cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's TensorFlow, enhancing diagnostic accuracy and patient outcomes. Biotricity Inc (BTCY) secured strategic alliances with three major group purchasing organizations, providing access to approximately 90% of U.S. hospitals. The company achieved positive adjusted EBITDA of $438,000 in the last quarter of fiscal 2025, indicating progress towards profitability. Biotricity Inc (BTCY) received regulatory approval in Saudi Arabia, aligning with its strategy to expand internationally and improve patient outcomes. Negative Points Biotricity Inc (BTCY) reported a net loss attributable to common stockholders of $11.9 million for the fiscal year ended March 31, 2025. The sales cycles for new partnerships and pilots with GPOs are lengthy, potentially delaying revenue realization. Despite improvements, the company still faces challenges in achieving profitability, with a net loss per share of $0.555 for the fiscal year. The company lacks in-house expertise to monetize its extensive data set, which could be a missed opportunity for additional revenue. Biotricity Inc (BTCY) anticipates that international market revenue contributions, such as from Saudi Arabia, may not significantly impact financials until 2026. Q & A Highlights Q: When can we expect greater acceleration in terms of revenue from your GPO relationships? A: Waqaas Al-Siddiq, CEO: The GPOs involve long sales cycles, often taking up to a year. We are currently engaging in pilots with large, multistate organizations. Revenue will start to trickle in as these pilots conclude and roll out over the next few quarters. Q: Which cost levers give you confidence that margins can stay above 80% in 2026? A: Waqaas Al-Siddiq, CEO: Our technology, particularly data analysis and device output, provides high margins. We've achieved economies of scale, reducing costs for each new device added to our platform, which helps maintain high margins. Q: Can the data set of over 1 trillion heartbeats be monetized beyond improving clinical algorithms? A: Waqaas Al-Siddiq, CEO: Yes, there is potential to monetize this data, especially given the focus on cardiac health. While we currently lack the in-house skill set to package and sell this data, we plan to invest in this area as we reach profitability. Q: What are your efforts in pursuing FDA clearance for your AI clinical model? A: Waqaas Al-Siddiq, CEO: We are in the process of analyzing data and bringing in experts for secondary input. We plan to present this to the FDA in a pre-submission meeting to ensure our approach aligns with their requirements. This is a complex process, but we are targeting significant opportunities. Q: How do you see the Saudi Arabian market impacting revenue for the rest of 2025 and next year? A: Waqaas Al-Siddiq, CEO: We expect significant impact in 2026. We aim for 20-30% of our business to be international in the coming years. For next year, we anticipate $0.5 million to $1 million in added revenue from international distribution partnerships. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
FY25 revenue up 14.3% YOY FY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continue FY25 operating expenses lower by 24.5% YOY Negative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9% Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "Fiscal 2025 has been another year of massive transformation for Biotricity. We've further utilized workflow automation, AI, and continued technological enhancements to drive substantial improvements in operational expenses, margin expansion, and revenue growth. This year, we demonstrated our ability to scale efficiently while maintaining high-quality service, bringing us to the doorstep of EBITDA breakeven and long-term profitability. The expansion of our Cardiac AI Cloud platform, supported by strategic partnerships with other industry leaders, showcases our commitment to revolutionizing medical diagnostics, chronic care management, and consumer healthcare. Leveraging over a trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability and growth, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Collaborative partnerships established during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America. Biotricity has also forged a strategic partnership focused on payor contracts for value based and managed care programs, both of which are new verticals for the Company. These developments underscore our dedication to advancing innovative, accessible, and high-quality cardiac care solutions." FY25 Financial Highlights Revenue increased 14.3% to $13.8 million compared with $12.1 million in FY24 Gross margin was 76.6% for the fiscal year ended March 31, 2025, as compared to 69.3% in FY24; this was the result of expansion in recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring cost structure. Net loss decreased 20% YOY to $11.9 million, or $0.56 per share, from a net loss of $14.9 million, or $1.66 per share, in FY24 Q4-FY25 Financial Highlights Revenue increased 16.5% to $3.7 million compared with $3.5 million in Q4 FY24 Gross margin was 80.4% for the three months ended March 31, 2025, as compared to 71.5% in the corresponding prior year quarter Net loss decreased 54% YOY to $2 million, or $0.08 per share, from a net loss of $4.4 million, or $0.47 per share, in Q4-FY24 Operating Highlights for FY25 FY25 recurring (TaaS) Technology Fees rose a robust 12% YOY to $12.6 million, representing over 10.5 times Device Sales revenue Company continues to maintain an impressive track record of customer retention, driven by high-quality customer and provider friendly support services, emphasis on accurate diagnostics, and user-friendly solutions. Developed a range of state-of-the-art products to service a total addressable market of $35 billion. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US Arrived at positive cash flows by growing subscription-based revenues, improving margins, and leveraging automation and experience to increase efficiencies of SG&A. Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Friday July 18, 2025 at 4:45 p.m. ET to discuss its financial results for fiscal year 2025 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity Fourth Quarter and FY 2025 Financial Results and Business Update Call Date: Friday, July 18, 2025 Time: 4:45pm ET (1:45pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13754989 Expiration: Friday, August 1, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Year ended March 31, 2025 Year ended March 31, 2024 3 months ended March 31, 2025 3 months ended March 31, 2024 $ $ $ $ Net loss attributable to common stockholders (11,942,000) (14,928,960) (2,022,133) (4,400,104) Add: Provision for income taxes - - - - Interest expense 3,262,038 3,018,803 891,752 814,943 Accretion and amortization expenses 1,945,769 2,178,873 165,560 598,063 Preferred stock dividends 3,520,821 834,677 86,396 217,634 EBITDA (3,213,372) (8,896,607) (878,425) (2,769,464) Add (Less) Share based compensation (1) 1,420,121 1,025,930 1,247,319 481,275 Other (income)/loss (2) 78,569 102,607 (49,405) (16,334) Gain (loss) upon convertible promissory notes conversion and redemption (2) 141267 (18,539) (8,391) (3,259) Fair value change on derivative liabilities (2) 595,442 (9,777) 127,162 (253,791) Adjusted EBITDA (977,973) (7,796,386) 438,260 (2,561,573) Weighted average number of common shares outstanding 21,524,884 8,991,766 21,524,884 9,441,667 Adjusted Loss per Share, Basic and Diluted (0.045) (0.867) 0.017 (0.271) (1) Share based compensation is a non-cash item (2) These items relate to financing transactions and do not reflect the Company's core operating activities Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts
